Three Billion Enters US Rare Disease Diagnostic Genetic Testing Market in Collaboration with SomaGen

3billion announced on the 20th that it has signed a Memorandum of Understanding (MOU) with Somagen, a global genomics company, to provide rare disease diagnostic genetic testing services targeting the U.S. healthcare market.

They agreed to combine Somagen’s extensive local network of medical professionals in the U.S. and its outstanding genomic data production capabilities with 3billion’s artificial intelligence rare disease diagnostic system. The goal is to provide fast and accurate diagnostic services to patients and families suffering from unexplained symptoms.

Somagen receives specimens from suspected rare disease patients referred by U.S. medical and research institutions and produces genetic variant data of the patients. This data will be used with 3billion’s AI rare disease diagnostic system to issue final diagnostic reports for medical professionals.

3billion’s artificial intelligence (AI) rare disease diagnostic system interprets millions of genetic variants found per patient with 99.4% accuracy in pathogenicity and selects the patient’s causative genetic variants within the Top-5 at a rate of 98.1%. This enables fast and accurate patient diagnosis. U.S. medical professionals can receive rapid and precise diagnostic services.

In the U.S., there is a growing demand for rapid diagnostic testing services for critically ill patients treated in neonatal intensive care units immediately after birth. Conventional exome and genome genetic tests usually take about 4 to 6 weeks for medical professionals to receive the final test results. Rapid diagnostic testing services provide results in as fast as 2 to 3 days, up to a maximum of one week. This helps quickly determine treatment directions and increases the patient’s chances of survival. This is why demand for such services is increasing in neonatal intensive care units.

Through the MOU, 3billion and Somagen will actively supply rapid diagnostic testing services. They plan to strengthen collaborative activities such as joint marketing of rare disease diagnostic genetic tests targeting rare disease patients in the U.S.

3billion has accumulated over 70,000 rare disease data cases through cooperation with more than 700 institutions in over 70 countries. It was listed on the KOSDAQ market on the 14th. Its overseas sales are rapidly growing, accounting for nearly 70% of total sales.

Somagen, established in Maryland, USA, is a global genomics and multi-omics analysis total solution provider. It has performed whole genome analysis on more than 20,000 Americans.